INTRODUCTION Immunoglobulin replacement therapy
Immunoglobulin replacement therapy is a key component in the treatment of patients with primary immunodeficiencies (PIDs), who are unable to produce sufficient functional antibodies to pathogens and are therefore susceptible to infections. 1 Immunoglobulin replacement therapy involves subcutaneous or intravenous administration of immunoglobulins that are purified from the plasma of healthy persons. Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) products are commercially produced by many different manufacturers. To make these products, manufacturers first collect large pools of plasma, typically from between 15,000 and 60,000 donors 2 living in a region at a certain time. They then process the plasma pools by inactivating potential viral pathogens, and purifying and stabilizing the immunoglobulin products. These manufacturing steps can vary among manufacturers and can affect the immunoglobulin products. 3 The overall immune experience of a particular donor population (eg, vaccination history) can also differ, and these differences also influence the quality of antibodies in the products. Therefore, the composition and efficacy of immunoglobulin products can vary among products from different manufacturers, or among different lots made by one manufacturer.
To reduce variation among products, regulatory agencies such as the US Food and Drug Administration (FDA) provide guidelines for the collection and manufacturing of approved products, 4, 5 for measuring immunologic properties of the final product, 4, 5 and for research studies that investigate new products. 6 FDA commercial regulations for the potency of immunoglobulin products specify minimum antibody levels for diphtheria, measles, and poliomyelitis, but they do not provide specific requirements for antibodies against other pathogens. 4 Although not mandated by the FDA for monitoring of existing commercial products, FDA research recommendations include measurement of overall immunoglobulin G (IgG) levels as well as pathogen-specific IgG levels for organisms such as Streptococcus pneumoniae and Haemophilus influenzae as secondary endpoints in efficacy studies of immunoglobulin products. 6 Streptococcus pneumoniae and pneumococcal vaccines S. pneumoniae (or pneumococcus) is an important human pathogen. Pneumococcus can cause respiratory tract infections such as community-acquired pneumonia and acute otitis media. It can also cause infections in normally sterile sites such as the bloodstream (bacteremia) or cerebrospinal fluid (meningitis). These infections are collectively referred to as invasive pneumococcal disease, or IPD. Pneumococcal infections are more common and also tend to be more severe in certain populations. Young children, elderly adults, and individuals with immunodeficiency and chronic medical conditions have increased susceptibility to, and increased morbidity from, pneumococcal infections. 7, 8 In the late 19th and early 20th centuries before the advent of antibiotics, patients with pneumococcal infections were treated with immune serum. 9, 10 Experience with serum treatments taught investigators the mechanisms of immune protection against pneumococcal infections. They learned that protection is mainly conferred by antibodies to the polysaccharide capsule that encases pathogenic pneumococci, and that immune protection from a particular strain is specific to its capsule serotype. 10, 11 Serologic differences in capsule led to the classification of pneumococci into more than 90 serotypes. 10 Antibodies to capsule provide protection against infections primarily by opsonizing pneumococci for clearance via phagocytosis. Observations from patients with various selective immunodeficiencies have supported opsonization as the primary in vivo pathway for defense against pneumococcal infections.
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This mechanism of immune protection has been used to develop pneumococcal vaccines. The early vaccine, pneumococcal polysaccharide vaccine (PPV23), contains capsular polysaccharide of 23 serotypes and is designed to elicit antibodies to capsule for those 23 serotypes. 13 PPV23, like many polysaccharides, elicits a T-independent immune response. 14 It is immunogenic among adults, but is not immunogenic in young children younger than 24 months of age. 15 Certain immunodeficiencies such as specific antibody deficiency (SAD), common variable immunodeficiency (CVID), and IgG subclass deficiency have also been associated with impaired responses to polysaccharide vaccines. 1, 16 Exploiting this observation, antibody response to PPV23 has become a part of the diagnostic evaluation for these types of PID. 16 To create effective vaccines for children, pneumococcal conjugate vaccines (PCVs) were developed by conjugating pneumococcal polysaccharides to a carrier protein. 17 PCVs elicit T-dependent immune responses 15 and are immunogenic in infants and young children. In the United States, the PCV containing 7 serotypes (PCV7) was introduced in 2000 with great success. 18 In 2010, the PCV containing 13 serotypes (PCV13) replaced PCV7 for use among US infants and children. 10 Since then, the use of PCV13 has been expanded to adults with PID or certain chronic conditions 19 and to adults ≥65 years of age. 20 
MEASUREMENT OF PNEUMOCOCCAL ANTIBODIES
The need to evaluate the immunogenicity of pneumococcal vaccines led to the development of methods to measure serotype-specific pneumococcal antibody levels. Sandwichtype enzyme-linked immunosorbent assays (ELISAs) were developed and subsequently refined to measure pneumococcal IgG antibodies for vaccine studies ( Fig. 1) . 21 In the 1970s and 1980s, first-generation ELISA overestimated antibody levels because of its nonspecific detection of cell-wall polysaccharide (C-PS) antibodies as well as other antibodies that do not opsonize pneumococci. 22 In the late 1980s and 1990s, second-generation ELISA incorporated preabsorption with C-PS and reduced detection of antibodies to C-PS. 23, 24 Nonetheless, this assay still detected enough nonfunctioning antibodies to limit its utility. 22 ELISA specificity was further improved by preabsorbing samples with both C-PS and another irrelevant capsular polysaccharide ( Fig. 1 ). This third-generation ELISA for pneumococcal IgG antibodies was standardized for global use as the World Health Organization (WHO) ELISA. In the early 2000s, a detailed protocol was made available at https://www.vaccine.uab.edu, 22 and remains the gold standard for pneumococcal antibody measurement. Following ELISA standardization, an IgG antibody level of 0.35 μg/mL has been accepted as the adequate response threshold for vaccine evaluation based on studies of PCV in infants and children. [25] [26] [27] [28] [29] Pneumococcal IgG antibody levels are also used to diagnose suspected immunodeficiency, but different thresholds are used for this purpose. Diagnostic recommendations published by the American Academy of Allergy, Asthma & Immunology (AAAAI) use a threshold of ≥1.3 μg/mL, 16 which was initially established based on limited data using Volume 58, December 2018 TRANSFUSION 3115 radioimmunoassay (RIA), a method that is no longer in use. 30 Other thresholds have also been used for diagnostic purposes, including the 0.35 μg/mL threshold used in vaccine studies. 21, 31 Recent studies have also proposed serotype-specific thresholds to identify subnormal responses to pneumococcal vaccines. 32 For clinical diagnostic applications, antibody levels are generally measured using multiplex bead array (or "Luminex") assays, since ELISA is impractical for measuring antibodies to many serotypes. However, different laboratories that perform these assays may produce different results, [33] [34] [35] which may limit their application for clinical use. 1 It is important to note that the thresholds that correspond with actual protection from pneumococcal infections can vary based on serotype, age, and type of infection. 7, 36 Furthermore, in certain populations (eg, elderly adults), pneumococcal antibody levels do not correlate well with functional antibody response. 37 The aforementioned FDA research recommendations also acknowledge that there is insufficient evidence to determine pneumococcal antibody levels that correspond with adequate protection from pneumococcal infections. 6 Although assays that measure pneumococcal antibody levels can provide evidence of immune response to a vaccine, they do not provide direct evidence of immune protection. An immunogenicity study of PCV7 illustrates this point. 38 In infants, administration of PCV7 resulted in pro- 20 OPA was developed in the 1970s and 1980s to study the biology of phagocytosis and patients with suspected immune dysfunction. 39 In the classic OPA, bacteria are incubated with a mixture of complement, phagocytes, and a serum sample to be tested (Fig. 2) . 40 To determine bacterial killing by serum antibodies, the reaction mixture is plated on agar plates and bacterial colonies are counted after overnight incubation. Because colony counting is tedious, chemiluminescence of activated phagocytes was often used as a surrogate indicator of killing. Early OPA used blood neutrophils, which are limited in quantity and vary among donors. These limitations made the classic killing OPA impractical for large-scale vaccine studies. Our laboratory invented multiplexed OPA (MOPA)-which allows analysis of multiple serotypes in a single assay run 41, 42 -and pioneered the automation of colony counting. 43, 44 In addition, our MOPA uses differentiated HL-60 cells as phagocytes, which improved assay reproducibility and provided phagocytes in unlimited quantities. 45 To enable all laboratories throughout the world to perform MOPA, we posted a detailed protocol for MOPA on a website (https://www.vaccine.uab.edu). Taken together, these steps that produced MOPA have made OPA a practical tool for vaccine studies.
Previously an OPA titer of at least 1:8 was used as the threshold to define an adequate response for vaccine studies. 17, 46, 47 This threshold was found to correlate with protection from invasive pneumococcal disease and corresponded with a serotype-specific pneumococcal IgG level of 0.20 μg/ mL based on studies of PCV in infants. 47 However, it was difficult to adopt a uniform threshold due to significant interlaboratory variations in assay sensitivities. Consequently, more recent guidelines recommend using fold increase in serotype-specific titers for vaccine evaluation. 17 A recent international collaboration showed that OPA can be standardized for 13 serotypes using a reference serum, 007sp, 48 a pneumococcal reference serum prepared by the FDA and international collaborators to be used worldwide to calibrate and standardize pneumococcal antibody assays. 49 Standardization has been shown to reduce interlaboratory variability in OPA results. 48 With increasing standardization of OPA, a new consensus OPA titer may emerge in the future.
PNEUMOCOCCAL ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS Studies using ELISA
Because pneumococcal infections are common among patients with PID, pneumococcal antibody levels have been studied extensively within immunoglobulin products. In 1992, Hamill et al. measured IgG levels to five pneumococcal serotypes in four different commercial preparations of IVIG using ELISA. 50 The ELISA used for the study may have lacked specificity because it used C-PS but not 22F PS absorption. Nevertheless, it showed that serotype-specific IgG levels varied across different preparations, which could be a result of differences in the donor pools and/or preparation methods. In 2008, a study by Lejtenyi 53 The study included 22 children, all of whom had been receiving the same IVIG product. Although peak serum IgG levels in children receiving IVIG were similar to levels from adult plasma pools, trough serum IgG levels were variable and not comparable to IgG levels from IVIG in most cases. Serum trough levels of pneumococcal antibodies were found to be protective (defined as ≥0.2 μg/mL in this study) for most of the participants.
A 2015 study by Knutsen et al. 54 used WHO ELISA (14 serotypes) to compare serotype-specific IgG levels in serum from pediatric patients receiving IVIG (with two potential preparations) vs SCIG. Peak and trough levels, as well as rate of decay in IgG levels varied by serotype. IVIG and SCIG did not differ in achieving therapeutic levels (using a threshold of ≥1.3 μg/mL). Trough IgG levels were protective for a similar percentage of patients receiving IVIG vs SCIG. However, there were significantly fewer nonserious bacterial infections in the SCIG group. In 2017, Simão-Gurge et al. 55 measured total IgG levels as well as pneumococcal IgG for six serotypes via WHO ELISA in trough serum samples from 21 pediatric and adult patients receiving IVIG. These levels were compared to total IgG and pneumococcal IgG levels from the IVIG preparations that were administered to the participants. Although all participants had protective antibody levels on each of four serial measurements when a threshold of ≥0.35 μg/mL was used, less than 30% had protective antibody levels on all four measurements when a threshold of ≥1.3 μg/mL was used. There was no correlation between trough total IgG levels and trough pneumococcal IgG levels. In general, there tends to be low lot-to-lot variability among lots of a product derived from an isolated geographic region. 53 However, other studies have observed variability in antibody levels among lots of a manufacturer's product produced using the same methods but from Volume 58, December 2018 TRANSFUSION 3117 different donor pools, 51 and similar serotype-specific trends in antibody levels among different manufacturers but from the same donor pool. 54 Taken together, these findings suggest that the immune experience of a particular population influences the composition of the final product.
Studies using OPA
With the realization that immunoglobulin preparations provide protection by opsonizing pneumococci, OPA has been used to assess different products since the 1980s. Early studies using chemiluminescence-based OPA have suggested that modification or treatment of immunoglobulin products during preparation could affect opsonic activity. 56 Two studies in the 1980s found variable opsonic activity among several immunoglobulin preparations using either a bacteriakilling OPA 57 or chemiluminescent OPA. 58 A 2004 study also reported that pepsin treatment during IVIG manufacturing may reduce opsonic activity. 3 In 2017, a study by Lee et al. 59 evaluated pneumococcal antibody function using OPA (MOPA, 26 serotypes) between 16 lots of IVIG from 2 different manufacturers as well as trough sera from IVIG recipients. Recipients' trough sera for products from both manufacturers had "sufficient" (≥1:8) opsonic activity in 24 of 26 total serotypes. Some studies have measured quantity and function of pneumococcal antibodies in immunoglobulin products, using both ELISA and OPA. In 2004, Mikolajczyk studied five lots of seven different IVIG preparations with thirdgeneration ELISA and OPA. 52 For certain serotypes and preparations, opsonic activity did not correlate with IgG levels. Overall, IgG levels among the various products were above their protective threshold of 0.15 μg/mL. Furthermore, serotype-specific IgG levels differed from those observed by Hamill in 1992, who evaluated some of the same preparations. 50 Mikolajczyk et al. concluded that this finding reflected change in the composition of immunoglobulin products over time. However, comparing the results of these two studies may be difficult given the substantial changes in the assay as discussed previously.
In 2014, Takahashi et al. 60 measured IgG levels for PCV13 serotypes using WHO ELISA, as well as opsonic activity for two serotypes using a killing OPA with differentiated HL-60 cells. The study investigated five lots each from four different commercial IVIG preparations, each prepared using different treatment steps. Observed differences in IgG levels between products did not necessarily correspond with the observed differences in opsonic index (opsonic index did not correlate with antibody levels).
Overall, studies using OPA demonstrated trends that were similar to those of studies of pneumococcal antibody levels, with findings of low lot-to-lot variability from individual manufacturers 52, 60 and significant variability in opsonic activity among the products of different manufacturers.
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CONCLUSIONS
Available evidence suggests that pneumococcal antibodies in immunoglobulin products can vary, largely due to different plasma donor pools or manufacturing processes, or both. 50, 51, 54 It is reasonable to measure pneumococcal antibodies as a means of monitoring such immunologic differences among products, since patients with PID often have pneumococcal infections, plasma donors have been vaccinated with pneumococcal vaccines, and pneumococcal antibody assays have been developed and extensively characterized during vaccine development. In addition, for the same reasons, measuring pneumococcal antibodies should be useful in the diagnosis and therapeutic monitoring of patients with PID. Measurement of pneumococcal antibodies has been greatly facilitated by assays that have been extremely wellcharacterized for vaccine development. Pneumococcal antibody levels can be measured with a standardized ELISA ("WHO ELISA") but this assay is cumbersome to perform for multiple serotypes. Numerous different multiplex bead array (Luminex) assays have been developed to improve the efficiency of pneumococcal antibody measurement; however, results are difficult to interpret because different assays can produce different results. 33, 61, 62 More recently, OPA has been standardized and MOPA has made OPA a practical and useful assay in vaccine studies. MOPA holds promise for the evaluation of immunoglobulin products. One must be aware of several caveats in the use of pneumococcal antibody assays. First, OPA measures the activities of both IgM and IgG antibodies, whereas ELISA/ Luminex assays measure IgG antibodies alone. This difference must be considered when interpreting the correlation studies of ELISA vs OPA, 52, 60 and it is also relevant in studying patients with PID because some PIDs can affect only one isotype. Because immunoglobulin preparations do not contain appreciable amounts of IgM, this is less important for product evaluation. Second, the antibody levels or opsonic activities that correspond with protection from infection are not well known, 61 and may differ for different serotypes or diseases (eg, sepsis vs otitis media). Third, analytic precision of OPA is sufficient to measure vaccine responses of a group but may not be sufficient for diagnosing individual patients. 
